Business Medical Devices News Public Health

Obesity Treatment Moving Toward Fragmented Clinical Approaches

PatrickDriscoll

2 Min Read

The obesity market is on the verge of new product introductions (especially drugs) and will soon become more fragmented by treatment options and competitors. The FDA has relented in the drug front, making it likely in the next 1-2 years (as we predicted) that the market will be split among appetite suppression, malabsorption, satiey and combination drugs. The trend is equally strong in the device arena, where the market dominance of restrictive devices (e.g., Lap-Band) will cede to artificial fullness, malabsorption, gastric emptying, and appetite suppression devices.

The obesity market is on the verge of new product introductions (especially drugs) and will soon become more fragmented by treatment options and competitors. The FDA has relented in the drug front, making it likely in the next 1-2 years (as we predicted) that the market will be split among appetite suppression, malabsorption, satiey and combination drugs. The trend is equally strong in the device arena, where the market dominance of restrictive devices (e.g., Lap-Band) will cede to artificial fullness, malabsorption, gastric emptying, and appetite suppression devices.

Below is illustrated the balance of the drug and device markets by type of obesity product.

Balance of Obesity Drugs and Device Markets by Type 2009-2019

Source: “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019″, Report #S835, MedMarket Diligence, LLC.

Of course, another way to view the obesity market that is supported by the general trend of clinical treatment options competing against each other irrespective of technology type is that the aggregate obesity market is comprised of a shifting balance among device and drug options. In any case, below is illustrated the relative balance of all drug and device markets for the treatment of obesity.

Balance of All Obesity Drugs and Device Markets by Type 2009-2019

Source: “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019″, Report #S835, MedMarket Diligence, LLC.

TAGGED:obesity

Share This Article

By PatrickDriscoll

Follow:

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.